Jaszewski R, Crane S A
Department of Gastroenterology, Veterans Administration Medical Center/Wayne State University Affiliated Hospitals, Allen Park, Michigan.
Am J Gastroenterol. 1987 Dec;82(12):1271-4.
Twenty-nine outpatients chronically ingesting daily aspirin or nonsteroidal antiinflammatory drugs for rheumatological disease, who had endoscopically proven gastric mucosal lesions worse than erythema, were evaluated for 4 wk in a randomized, double-blind trial comparing 15(R)-15-methyl prostaglandin E2 (Arbacet) (10 micrograms, 0.5 h before each meal and at bedtime) with placebo. Patients continued their usual daily dose of antiarthritic medication throughout the study period, and an endoscopy was performed on the final day to assess healing. Five of 14 patients (36%) taking Arbacet and two of 15 patients (13%) in the placebo group had complete healing of their gastric lesions after 4 wk. Arbacet at a daily dose of 40 micrograms is not significantly better than placebo in healing gastric lesions caused by aspirin or nonsteroidal antiinflammatory drugs, if antiinflammatory therapy is continued.
29例因风湿性疾病长期每日服用阿司匹林或非甾体抗炎药、经内镜证实胃黏膜病变比红斑更严重的门诊患者，在一项随机双盲试验中接受了4周的评估，该试验比较了15(R)-15-甲基前列腺素E2（Arbacet）（每餐饭前0.5小时及睡前服用10微克）与安慰剂的效果。在整个研究期间，患者继续服用其通常的每日抗关节炎药物剂量，并在最后一天进行内镜检查以评估愈合情况。服用Arbacet的14例患者中有五例（36%），安慰剂组的15例患者中有两例（13%）在4周后胃病变完全愈合。如果继续进行抗炎治疗，每日剂量40微克的Arbacet在治愈由阿司匹林或非甾体抗炎药引起的胃病变方面并不比安慰剂显著更好。
